Not the usual polished presentation we have come to expect from...

Not the usual polished presentation we have come to expect from BOT,,, some may recall an announcement last year that was added to a few days later,, those few words were along the lines of,,"continued to show benefit beyond the Trial Period"

Personally don't think the data has had enough set of eyes and enough time to be analysed comprehensively ,,

Moving on toward Phase III would indicate that there was "significant benefit to the trial patients" as required by the DSMB. additionally the FDA application would require documentation that showed Trial Patient benefits..

We are all on the side line until further clarification .. the below was posted by another poster but it is the headline topics the market will be interested in ....



waiting for further updates ,, Market always decides ....